The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women
Authors:
- J.F.R. RobertsonJRJ.F.R. Robertson
- R.W. BlameyRBR.W. Blamey
- 1 May 2003
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 39 (7) , 861-869
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Combined use of goserelin (zoladex) and anastrozole (arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer — a study of its clinical and endocrine effectsEuropean Journal of Cancer, 2001
- Systemic adjuvant treatment for premenopausal node-negative breast cancerEuropean Journal of Cancer, 2000
- A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancerEuropean Journal of Cancer, 1995
- Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancerEuropean Journal of Cancer, 1993
- Goserelin depot in the treatment of premenopausal advanced breast cancerEuropean Journal of Cancer, 1992
- Zoladex in Advanced Breast CancerHormone Research, 1989
- Effect of LHRH agonist, Zoladex, on ovarian histologyBritish Journal of Surgery, 1988
- LHRH-Agonist treatment in clinical and experimental human breast cancerJournal of Steroid Biochemistry, 1985
- TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1982
- ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1The Lancet, 1896